ProKidney Corp - Class A — Liquidità (NASDAQ:PROK) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative —-77.09 M-90.07 M-126.35 M-120.12 M -120.12 M Flussi di cassa derivanti dalle attività di investimento —-1.74 M-329.98 M20.41 M103.97 M 103.97 M Liquidità derivante dalle attività di finanziamento —548.52 M-9.55 M144.41 M25.57 M 25.57 M Liquidità libera —-78.94 M-124.27 M-155.86 M-135.31 M -135.31 M

Notizie

ProKidney nomina Greg Madison come chief commercial officer

BofA conferma rating Underperform su ProKidney con target a $1

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright avvia copertura su ProKidney con rating Buy e target di $12

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual